These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. New treatments for metastic prostate cancer. Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400 [TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. Paller CJ; Antonarakis ES Hum Vaccin Immunother; 2012 Apr; 8(4):509-19. PubMed ID: 22336881 [TBL] [Abstract][Full Text] [Related]
10. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945 [TBL] [Abstract][Full Text] [Related]
11. Therapy: An immune one-two punch. Bourzac K Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788 [No Abstract] [Full Text] [Related]
12. Managed care considerations. A new era of advanced prostate cancer management. Muller R Manag Care; 2011 Sep; 20(9 Suppl 5):5. PubMed ID: 22043721 [No Abstract] [Full Text] [Related]
13. Provenge: combating prostate cancer with a vengeance? Schwaab T; Pili R Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304 [No Abstract] [Full Text] [Related]
14. Sipuleucel-T (Provenge(®))-Autopsy of an Innovative Paradigm Change in Cancer Treatment: Why a Single-Product Biotech Company Failed to Capitalize on its Breakthrough Invention. Jarosławski S; Toumi M BioDrugs; 2015 Oct; 29(5):301-7. PubMed ID: 26403092 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in castration-resistant prostate cancer: integrating sipuleucel-T into our current treatment paradigm. Garcia JA; Dreicer R Oncology (Williston Park); 2011 Mar; 25(3):242-9. PubMed ID: 21548467 [TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for advanced prostate cancer: a novel treatment option to improve survival. Peskin SR Manag Care; 2011 Sep; 20(9 Suppl 5):3-4, 6-11. PubMed ID: 22046617 [TBL] [Abstract][Full Text] [Related]
18. Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Buonerba C; Ferro M; Di Lorenzo G Expert Rev Anticancer Ther; 2011 Jan; 11(1):25-8. PubMed ID: 21166508 [TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of sipuleucel-T immunotherapy in castration-resistant prostate cancer. Holko P; Kawalec P Expert Rev Anticancer Ther; 2014 Jan; 14(1):63-73. PubMed ID: 24224852 [TBL] [Abstract][Full Text] [Related]
20. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Wei XX; Fong L; Small EJ Expert Rev Vaccines; 2015; 14(12):1529-41. PubMed ID: 26488270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]